KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Net Margin: 2017-2025

Historic Net Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Sep 2025 value amounting to -120.61%.

  • Aquestive Therapeutics' Net Margin fell 3562.00% to -120.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 524.32%, marking a year-over-year increase of 58407.00%. This contributed to the annual value of -4,378.67% for FY2024, which is 436311.00% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' Net Margin stood at -120.61%, which was up 10.95% from -135.44% recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Net Margin registered a high of 72.46% during Q1 2023, and its lowest value of -618.35% during Q2 2021.
  • Moreover, its 3-year median value for Net Margin was -61.42% (2023), whereas its average is -66.75%.
  • In the last 5 years, Aquestive Therapeutics' Net Margin spiked by 41,458bps in 2022 and then plummeted by 17,889bps in 2024.
  • Aquestive Therapeutics' Net Margin (Quarterly) stood at -261.28% in 2021, then skyrocketed by 14,565bps to -115.63% in 2022, then surged by 5,421bps to -61.42% in 2023, then surged by 9,959bps to 38.17% in 2024, then plummeted by 3,562bps to -120.61% in 2025.
  • Its Net Margin was -120.61% in Q3 2025, compared to -135.44% in Q2 2025 and -262.96% in Q1 2025.